<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Inhibition of cardiac late <z:chebi fb="199" ids="26708">sodium</z:chebi> current (late I(Na)) is a strategy to suppress <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> and <z:chebi fb="199" ids="26708">sodium</z:chebi>-dependent calcium overload associated with <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e> and <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Current inhibitors of late I(Na) are unselective and can be proarrhythmic </plain></SENT>
<SENT sid="2" pm="."><plain>This study introduces GS967 (6-[4-(trifluoromethoxy)<z:chebi fb="1" ids="30396">phenyl</z:chebi>]-3-(<z:chebi fb="0" ids="50127">trifluoromethyl</z:chebi>)-[1,2,4]triazolo[4,3-a]<z:chebi fb="1" ids="16227">pyridine</z:chebi>), a potent and selective inhibitor of late I(Na), and demonstrates its effectiveness to suppress <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The effects of GS967 on rabbit ventricular myocyte ion channel currents and action potentials were determined </plain></SENT>
<SENT sid="4" pm="."><plain>Anti-arrhythmic actions of GS967 were characterized in ex vivo and in vivo rabbit models of reduced repolarization reserve and <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>GS967 inhibited Anemonia sulcata toxin II (ATX-II)-induced late I(Na) in ventricular myocytes and isolated hearts with IC(50) values of 0.13 and 0.21 ÂµM, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Reduction of peak I(Na) by GS967 was minimal at a holding potential of -120 mV but increased at -80 mV </plain></SENT>
<SENT sid="7" pm="."><plain>GS967 did not prolong action potential duration or the QRS interval </plain></SENT>
<SENT sid="8" pm="."><plain>GS967 prevented and reversed proarrhythmic effects (afterdepolarizations and <z:hpo ids='HP_0001664'>torsades de pointes</z:hpo>) of the late I(Na) enhancer ATX-II and the I(Kr) inhibitor E-4031 in isolated ventricular myocytes and hearts </plain></SENT>
<SENT sid="9" pm="."><plain>GS967 significantly attenuated the proarrhythmic effects of methoxamine+clofilium and suppressed <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>GS967 was more potent and effective to reduce late I(Na) and <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> than either flecainide or ranolazine </plain></SENT>
<SENT sid="11" pm="."><plain>Results of <z:hpo ids='HP_0000001'>all</z:hpo> studies and assays of binding and activity of GS967 at numerous receptors, transporters, and enzymes indicated that GS967 selectively inhibited late I(Na) </plain></SENT>
<SENT sid="12" pm="."><plain>In summary, GS967 selectively suppressed late I(Na) and prevented and/or reduced the incidence of experimentally induced <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> in rabbit myocytes and hearts </plain></SENT>
</text></document>